| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gene Expression Profiling | 23 | 2022 | 345 | 3.560 |
Why?
|
| Software | 8 | 2022 | 133 | 2.890 |
Why?
|
| Humans | 70 | 2023 | 4119 | 2.440 |
Why?
|
| Transcription Factors | 15 | 2022 | 256 | 2.440 |
Why?
|
| Chromatin | 10 | 2023 | 49 | 2.400 |
Why?
|
| Single-Cell Analysis | 8 | 2022 | 67 | 2.380 |
Why?
|
| Sequence Analysis, DNA | 7 | 2021 | 249 | 2.090 |
Why?
|
| Gene Expression Regulation | 7 | 2023 | 210 | 1.990 |
Why?
|
| Histones | 9 | 2022 | 36 | 1.840 |
Why?
|
| Computational Biology | 9 | 2019 | 164 | 1.830 |
Why?
|
| Induced Pluripotent Stem Cells | 7 | 2023 | 43 | 1.620 |
Why?
|
| Cell Differentiation | 17 | 2023 | 199 | 1.600 |
Why?
|
| Myeloproliferative Disorders | 5 | 2021 | 9 | 1.570 |
Why?
|
| DNA | 9 | 2022 | 102 | 1.570 |
Why?
|
| RNA, Long Noncoding | 9 | 2023 | 36 | 1.550 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 7 | 2017 | 138 | 1.430 |
Why?
|
| Algorithms | 10 | 2019 | 165 | 1.400 |
Why?
|
| Transcriptome | 6 | 2022 | 201 | 1.380 |
Why?
|
| Animals | 33 | 2023 | 1545 | 1.360 |
Why?
|
| Genomics | 6 | 2023 | 143 | 1.350 |
Why?
|
| Bone Marrow | 4 | 2021 | 58 | 1.200 |
Why?
|
| Cluster Analysis | 8 | 2022 | 62 | 1.150 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 6 | 2023 | 13 | 1.130 |
Why?
|
| Transcription, Genetic | 5 | 2021 | 133 | 1.130 |
Why?
|
| Mice | 28 | 2023 | 737 | 1.110 |
Why?
|
| Primary Myelofibrosis | 3 | 2021 | 6 | 1.070 |
Why?
|
| Calreticulin | 2 | 2021 | 2 | 1.000 |
Why?
|
| Epigenesis, Genetic | 6 | 2020 | 102 | 0.920 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 5 | 2020 | 50 | 0.920 |
Why?
|
| DNA-Binding Proteins | 5 | 2022 | 139 | 0.910 |
Why?
|
| Signal Transduction | 8 | 2022 | 261 | 0.870 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2022 | 8 | 0.850 |
Why?
|
| Chromosome Deletion | 1 | 2022 | 45 | 0.840 |
Why?
|
| Megakaryocytes | 1 | 2021 | 9 | 0.820 |
Why?
|
| Frameshift Mutation | 1 | 2021 | 32 | 0.820 |
Why?
|
| Chromatin Immunoprecipitation | 4 | 2016 | 26 | 0.800 |
Why?
|
| DNA Methylation | 7 | 2020 | 186 | 0.770 |
Why?
|
| Cell Proliferation | 12 | 2022 | 129 | 0.760 |
Why?
|
| Cells, Cultured | 10 | 2022 | 261 | 0.750 |
Why?
|
| DNA Footprinting | 2 | 2019 | 7 | 0.730 |
Why?
|
| Neoplastic Stem Cells | 5 | 2023 | 21 | 0.730 |
Why?
|
| Inflammation | 4 | 2023 | 179 | 0.720 |
Why?
|
| Pluripotent Stem Cells | 5 | 2022 | 9 | 0.680 |
Why?
|
| Receptors, CXCR6 | 1 | 2018 | 1 | 0.680 |
Why?
|
| Fatty Liver | 1 | 2018 | 8 | 0.680 |
Why?
|
| Apoptosis | 10 | 2023 | 94 | 0.680 |
Why?
|
| Insulin-Secreting Cells | 2 | 2017 | 15 | 0.660 |
Why?
|
| Fusion Proteins, bcr-abl | 6 | 2023 | 13 | 0.650 |
Why?
|
| Deoxyribonuclease I | 2 | 2016 | 3 | 0.650 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2019 | 173 | 0.640 |
Why?
|
| Hematopoietic Stem Cells | 6 | 2022 | 50 | 0.620 |
Why?
|
| Nuclear Proteins | 4 | 2022 | 83 | 0.610 |
Why?
|
| Liver Neoplasms | 3 | 2023 | 18 | 0.610 |
Why?
|
| Pancreas | 4 | 2021 | 11 | 0.600 |
Why?
|
| Male | 16 | 2022 | 1811 | 0.590 |
Why?
|
| Promoter Regions, Genetic | 6 | 2019 | 99 | 0.590 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2021 | 39 | 0.580 |
Why?
|
| Models, Biological | 3 | 2008 | 115 | 0.580 |
Why?
|
| Disease Models, Animal | 7 | 2023 | 143 | 0.560 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 4 | 0.560 |
Why?
|
| Insulin | 2 | 2017 | 61 | 0.540 |
Why?
|
| Sequence Analysis, RNA | 5 | 2022 | 90 | 0.540 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2022 | 111 | 0.530 |
Why?
|
| Janus Kinase 2 | 3 | 2019 | 7 | 0.530 |
Why?
|
| Receptor, PAR-1 | 1 | 2015 | 2 | 0.520 |
Why?
|
| Thrombin | 1 | 2015 | 4 | 0.520 |
Why?
|
| Cell Lineage | 3 | 2018 | 42 | 0.510 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2014 | 6 | 0.500 |
Why?
|
| Bone Marrow Cells | 4 | 2022 | 26 | 0.500 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2014 | 12 | 0.490 |
Why?
|
| Databases, Genetic | 2 | 2013 | 62 | 0.480 |
Why?
|
| Leukemia, Myeloid | 2 | 2023 | 8 | 0.460 |
Why?
|
| Binding Sites | 5 | 2019 | 73 | 0.450 |
Why?
|
| Macrophages | 4 | 2023 | 124 | 0.440 |
Why?
|
| Blood Cells | 1 | 2012 | 11 | 0.430 |
Why?
|
| Models, Statistical | 3 | 2011 | 46 | 0.430 |
Why?
|
| CpG Islands | 5 | 2020 | 51 | 0.430 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2021 | 170 | 0.420 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2023 | 17 | 0.420 |
Why?
|
| Hepatocyte Nuclear Factor 6 | 2 | 2021 | 2 | 0.420 |
Why?
|
| Protein Binding | 7 | 2019 | 97 | 0.410 |
Why?
|
| Metabolomics | 1 | 2011 | 24 | 0.400 |
Why?
|
| Multigene Family | 3 | 2008 | 30 | 0.400 |
Why?
|
| Myocardial Infarction | 2 | 2022 | 28 | 0.400 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2011 | 47 | 0.400 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 2 | 2022 | 23 | 0.400 |
Why?
|
| Kidney | 4 | 2023 | 38 | 0.380 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2022 | 14 | 0.380 |
Why?
|
| NF-kappa B | 2 | 2023 | 26 | 0.380 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2019 | 40 | 0.380 |
Why?
|
| Liver | 3 | 2019 | 61 | 0.370 |
Why?
|
| Markov Chains | 5 | 2014 | 20 | 0.360 |
Why?
|
| Cell Cycle Proteins | 2 | 2017 | 33 | 0.360 |
Why?
|
| Mutation | 4 | 2023 | 608 | 0.350 |
Why?
|
| Up-Regulation | 3 | 2022 | 62 | 0.350 |
Why?
|
| Female | 12 | 2022 | 2147 | 0.350 |
Why?
|
| STAT1 Transcription Factor | 2 | 2019 | 2 | 0.350 |
Why?
|
| Janus Kinase 1 | 2 | 2019 | 2 | 0.340 |
Why?
|
| Stem Cells | 3 | 2023 | 40 | 0.340 |
Why?
|
| Interferon-alpha | 2 | 2019 | 8 | 0.340 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2021 | 95 | 0.330 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2019 | 23 | 0.330 |
Why?
|
| RNA, Messenger | 4 | 2018 | 263 | 0.330 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2021 | 93 | 0.320 |
Why?
|
| Neoplasms | 4 | 2017 | 135 | 0.320 |
Why?
|
| Endothelial Cells | 3 | 2022 | 26 | 0.320 |
Why?
|
| T-Box Domain Proteins | 2 | 2018 | 7 | 0.320 |
Why?
|
| Models, Immunological | 1 | 2007 | 7 | 0.310 |
Why?
|
| K562 Cells | 3 | 2019 | 9 | 0.310 |
Why?
|
| Organoids | 4 | 2022 | 7 | 0.310 |
Why?
|
| Learning | 1 | 2007 | 4 | 0.300 |
Why?
|
| In Situ Hybridization | 1 | 2007 | 34 | 0.300 |
Why?
|
| Drosophila melanogaster | 1 | 2007 | 25 | 0.290 |
Why?
|
| Cell Line | 5 | 2021 | 137 | 0.290 |
Why?
|
| Aging | 3 | 2020 | 92 | 0.290 |
Why?
|
| Biomarkers, Tumor | 3 | 2019 | 148 | 0.290 |
Why?
|
| Pancreatic Neoplasms | 2 | 2016 | 11 | 0.290 |
Why?
|
| Aged | 8 | 2021 | 580 | 0.280 |
Why?
|
| Adult | 8 | 2022 | 944 | 0.280 |
Why?
|
| Histone-Lysine N-Methyltransferase | 4 | 2022 | 27 | 0.280 |
Why?
|
| Mice, Inbred C57BL | 7 | 2020 | 226 | 0.280 |
Why?
|
| MicroRNAs | 2 | 2022 | 82 | 0.280 |
Why?
|
| Genome, Human | 2 | 2018 | 104 | 0.260 |
Why?
|
| Programming Languages | 1 | 2005 | 6 | 0.260 |
Why?
|
| Computer Graphics | 1 | 2005 | 10 | 0.260 |
Why?
|
| User-Computer Interface | 1 | 2005 | 19 | 0.260 |
Why?
|
| Nucleic Acid Conformation | 3 | 2019 | 20 | 0.250 |
Why?
|
| Carcinogenesis | 2 | 2022 | 17 | 0.250 |
Why?
|
| Mice, Knockout | 3 | 2018 | 149 | 0.240 |
Why?
|
| Myocytes, Cardiac | 2 | 2022 | 13 | 0.240 |
Why?
|
| Islets of Langerhans | 2 | 2021 | 11 | 0.240 |
Why?
|
| Antigens, CD34 | 2 | 2021 | 16 | 0.240 |
Why?
|
| Peyer's Patches | 1 | 2023 | 1 | 0.230 |
Why?
|
| Mastocytosis, Systemic | 1 | 2023 | 2 | 0.230 |
Why?
|
| Bayes Theorem | 3 | 2012 | 42 | 0.230 |
Why?
|
| Documentation | 1 | 2023 | 3 | 0.230 |
Why?
|
| Myofibroblasts | 1 | 2023 | 2 | 0.230 |
Why?
|
| Gene Library | 1 | 2023 | 20 | 0.230 |
Why?
|
| Kidney Glomerulus | 1 | 2023 | 5 | 0.230 |
Why?
|
| Proteomics | 1 | 2023 | 77 | 0.230 |
Why?
|
| Nucleosomes | 2 | 2019 | 8 | 0.230 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2023 | 33 | 0.220 |
Why?
|
| Cysts | 1 | 2022 | 6 | 0.220 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2022 | 4 | 0.220 |
Why?
|
| Dendritic Cells | 3 | 2023 | 81 | 0.220 |
Why?
|
| Adoptive Transfer | 2 | 2021 | 11 | 0.220 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 41 | 0.220 |
Why?
|
| Cell Movement | 3 | 2021 | 45 | 0.220 |
Why?
|
| Atrial Remodeling | 1 | 2022 | 2 | 0.220 |
Why?
|
| Ventricular Remodeling | 1 | 2022 | 12 | 0.220 |
Why?
|
| Benchmarking | 1 | 2022 | 7 | 0.220 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2022 | 20 | 0.220 |
Why?
|
| Cell Communication | 1 | 2022 | 11 | 0.220 |
Why?
|
| Podocytes | 1 | 2022 | 4 | 0.220 |
Why?
|
| Nephrotic Syndrome | 1 | 2022 | 8 | 0.220 |
Why?
|
| Heart Failure | 1 | 2022 | 16 | 0.210 |
Why?
|
| Haploinsufficiency | 1 | 2022 | 15 | 0.210 |
Why?
|
| Proteome | 1 | 2022 | 57 | 0.210 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2021 | 6 | 0.210 |
Why?
|
| Thrombopoiesis | 1 | 2021 | 2 | 0.210 |
Why?
|
| Linear Models | 2 | 2012 | 20 | 0.210 |
Why?
|
| Colitis | 1 | 2021 | 5 | 0.210 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 31 | 0.200 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 39 | 0.200 |
Why?
|
| Flow Cytometry | 1 | 2021 | 71 | 0.200 |
Why?
|
| Middle Aged | 6 | 2019 | 843 | 0.200 |
Why?
|
| Ephrin-A5 | 1 | 2021 | 1 | 0.200 |
Why?
|
| Monocytes | 2 | 2019 | 57 | 0.200 |
Why?
|
| Cell Physiological Phenomena | 1 | 2020 | 2 | 0.200 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 33 | 0.200 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 62 | 0.190 |
Why?
|
| Protein Kinases | 2 | 2023 | 11 | 0.190 |
Why?
|
| Receptors, IgG | 1 | 2020 | 5 | 0.190 |
Why?
|
| Neural Inhibition | 1 | 2020 | 1 | 0.190 |
Why?
|
| GABAergic Neurons | 1 | 2020 | 3 | 0.190 |
Why?
|
| Interneurons | 1 | 2020 | 4 | 0.190 |
Why?
|
| Synapses | 1 | 2020 | 10 | 0.190 |
Why?
|
| Endocytosis | 1 | 2020 | 8 | 0.190 |
Why?
|
| Computer Simulation | 4 | 2012 | 96 | 0.190 |
Why?
|
| Phenotype | 5 | 2023 | 479 | 0.180 |
Why?
|
| Echinomycin | 1 | 2019 | 1 | 0.180 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2019 | 1 | 0.180 |
Why?
|
| Hep G2 Cells | 1 | 2019 | 8 | 0.180 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 77 | 0.180 |
Why?
|
| Infliximab | 1 | 2019 | 3 | 0.180 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 10 | 0.180 |
Why?
|
| Pyrimidines | 1 | 2019 | 10 | 0.180 |
Why?
|
| Models, Genetic | 2 | 2019 | 117 | 0.180 |
Why?
|
| STAT2 Transcription Factor | 1 | 2019 | 1 | 0.180 |
Why?
|
| Cell Line, Tumor | 4 | 2021 | 161 | 0.170 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2019 | 24 | 0.170 |
Why?
|
| STAT3 Transcription Factor | 1 | 2019 | 10 | 0.170 |
Why?
|
| Myeloid Cells | 1 | 2019 | 31 | 0.170 |
Why?
|
| Fetal Proteins | 1 | 2018 | 2 | 0.170 |
Why?
|
| Mesoderm | 1 | 2018 | 4 | 0.170 |
Why?
|
| Cytochrome P-450 CYP4A | 1 | 2018 | 1 | 0.170 |
Why?
|
| Hepatocytes | 1 | 2018 | 12 | 0.170 |
Why?
|
| Energy Metabolism | 1 | 2019 | 47 | 0.170 |
Why?
|
| RNA | 1 | 2019 | 54 | 0.170 |
Why?
|
| Exocytosis | 2 | 2017 | 4 | 0.170 |
Why?
|
| Methylation | 2 | 2019 | 5 | 0.170 |
Why?
|
| Cyclin E | 1 | 2018 | 1 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2018 | 1 | 0.170 |
Why?
|
| Oncogene Proteins | 1 | 2018 | 13 | 0.170 |
Why?
|
| Stress, Physiological | 1 | 2018 | 30 | 0.170 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2018 | 20 | 0.170 |
Why?
|
| STAT4 Transcription Factor | 1 | 2018 | 2 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2018 | 4 | 0.170 |
Why?
|
| Arthritis, Juvenile | 1 | 2018 | 2 | 0.160 |
Why?
|
| Gene Expression | 5 | 2019 | 138 | 0.160 |
Why?
|
| Ligands | 3 | 2023 | 10 | 0.160 |
Why?
|
| HMGB2 Protein | 1 | 2018 | 2 | 0.160 |
Why?
|
| Protein Interaction Domains and Motifs | 2 | 2016 | 11 | 0.160 |
Why?
|
| CCCTC-Binding Factor | 1 | 2018 | 10 | 0.160 |
Why?
|
| CCR5 Receptor Antagonists | 1 | 2018 | 1 | 0.160 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 9 | 0.160 |
Why?
|
| Imidazoles | 1 | 2018 | 12 | 0.160 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 206 | 0.160 |
Why?
|
| Epiphyses, Slipped | 1 | 2017 | 1 | 0.160 |
Why?
|
| Femur | 1 | 2017 | 2 | 0.160 |
Why?
|
| Bone Diseases, Developmental | 1 | 2017 | 5 | 0.160 |
Why?
|
| Hindlimb | 1 | 2017 | 3 | 0.160 |
Why?
|
| alpha-2-HS-Glycoprotein | 1 | 2017 | 5 | 0.160 |
Why?
|
| DNA Repair | 1 | 2018 | 60 | 0.160 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 92 | 0.160 |
Why?
|
| Proteogenomics | 1 | 2017 | 3 | 0.160 |
Why?
|
| Microscopy | 1 | 2017 | 8 | 0.160 |
Why?
|
| SOXD Transcription Factors | 1 | 2017 | 1 | 0.150 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2017 | 7 | 0.150 |
Why?
|
| Cytokines | 3 | 2023 | 75 | 0.150 |
Why?
|
| Consensus Sequence | 1 | 2016 | 9 | 0.150 |
Why?
|
| Transcriptional Activation | 1 | 2016 | 14 | 0.150 |
Why?
|
| Activins | 1 | 2016 | 1 | 0.150 |
Why?
|
| Nodal Protein | 1 | 2016 | 2 | 0.150 |
Why?
|
| Cystic Fibrosis | 1 | 2016 | 10 | 0.150 |
Why?
|
| Carcinoma, Papillary | 1 | 2016 | 4 | 0.140 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2016 | 3 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2016 | 6 | 0.140 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 23 | 0.140 |
Why?
|
| Life Expectancy | 1 | 2016 | 4 | 0.140 |
Why?
|
| Empirical Research | 1 | 2016 | 1 | 0.140 |
Why?
|
| Fibroblasts | 3 | 2022 | 71 | 0.140 |
Why?
|
| Databases, Factual | 1 | 2016 | 12 | 0.140 |
Why?
|
| Models, Theoretical | 1 | 2016 | 26 | 0.140 |
Why?
|
| Microfilament Proteins | 1 | 2015 | 17 | 0.140 |
Why?
|
| Mouse Embryonic Stem Cells | 1 | 2015 | 7 | 0.130 |
Why?
|
| Time Factors | 3 | 2022 | 115 | 0.130 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 58 | 0.130 |
Why?
|
| Proteins | 1 | 2016 | 77 | 0.130 |
Why?
|
| Gene Regulatory Networks | 1 | 2015 | 70 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2016 | 105 | 0.130 |
Why?
|
| Microarray Analysis | 1 | 2015 | 14 | 0.130 |
Why?
|
| Protein Footprinting | 1 | 2014 | 1 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 3 | 2019 | 34 | 0.120 |
Why?
|
| Infant | 3 | 2021 | 267 | 0.120 |
Why?
|
| Base Sequence | 3 | 2019 | 275 | 0.120 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 14 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2018 | 120 | 0.120 |
Why?
|
| Mast Cells | 2 | 2023 | 10 | 0.110 |
Why?
|
| Classification | 2 | 2011 | 6 | 0.110 |
Why?
|
| Pattern Recognition, Automated | 3 | 2010 | 20 | 0.110 |
Why?
|
| Fibrosis | 2 | 2023 | 8 | 0.110 |
Why?
|
| Embryonic Stem Cells | 1 | 2012 | 24 | 0.110 |
Why?
|
| Pancreatic Diseases | 2 | 2021 | 3 | 0.100 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2023 | 11 | 0.100 |
Why?
|
| Genetic Variation | 1 | 2012 | 189 | 0.100 |
Why?
|
| Base Pairing | 2 | 2022 | 9 | 0.100 |
Why?
|
| Lysine | 2 | 2022 | 5 | 0.100 |
Why?
|
| Adaptation, Physiological | 1 | 2011 | 27 | 0.100 |
Why?
|
| Arabidopsis | 1 | 2011 | 97 | 0.100 |
Why?
|
| Human Embryonic Stem Cells | 2 | 2021 | 5 | 0.090 |
Why?
|
| Infant, Newborn | 2 | 2021 | 119 | 0.090 |
Why?
|
| Calcitriol | 1 | 2009 | 2 | 0.090 |
Why?
|
| Receptors, Calcitriol | 1 | 2009 | 2 | 0.090 |
Why?
|
| Keratinocytes | 1 | 2009 | 20 | 0.090 |
Why?
|
| Hydrogen Peroxide | 1 | 2009 | 22 | 0.090 |
Why?
|
| Interferon-beta | 1 | 2009 | 4 | 0.090 |
Why?
|
| Cell Nucleus | 1 | 2009 | 36 | 0.090 |
Why?
|
| Multiple Sclerosis | 1 | 2009 | 14 | 0.090 |
Why?
|
| Calgranulin B | 2 | 2019 | 12 | 0.090 |
Why?
|
| Calgranulin A | 2 | 2019 | 12 | 0.090 |
Why?
|
| Embryoid Bodies | 2 | 2022 | 8 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 99 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2022 | 322 | 0.090 |
Why?
|
| RNA, Small Interfering | 2 | 2020 | 35 | 0.080 |
Why?
|
| Prognosis | 2 | 2019 | 196 | 0.080 |
Why?
|
| Biomarkers | 2 | 2021 | 188 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2020 | 37 | 0.080 |
Why?
|
| Lymphoid Tissue | 1 | 2007 | 4 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 17 | 0.080 |
Why?
|
| Killer Cells, Natural | 1 | 2007 | 24 | 0.080 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2018 | 9 | 0.080 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 111 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2007 | 60 | 0.080 |
Why?
|
| Cellular Senescence | 2 | 2018 | 26 | 0.080 |
Why?
|
| Microscopy, Fluorescence | 2 | 2017 | 25 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2007 | 98 | 0.070 |
Why?
|
| Fetal Blood | 2 | 2019 | 9 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 78 | 0.070 |
Why?
|
| Trans-Activators | 2 | 2017 | 25 | 0.070 |
Why?
|
| Child, Preschool | 2 | 2018 | 378 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 2 | 2016 | 6 | 0.070 |
Why?
|
| Adolescent | 2 | 2018 | 493 | 0.070 |
Why?
|
| Child | 2 | 2018 | 557 | 0.070 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 39 | 0.070 |
Why?
|
| Young Adult | 2 | 2016 | 345 | 0.070 |
Why?
|
| Artificial Intelligence | 1 | 2005 | 21 | 0.070 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2023 | 3 | 0.060 |
Why?
|
| Splenomegaly | 1 | 2023 | 2 | 0.060 |
Why?
|
| Intestine, Small | 1 | 2023 | 5 | 0.060 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 19 | 0.060 |
Why?
|
| Intestinal Mucosa | 1 | 2023 | 14 | 0.060 |
Why?
|
| Feedback | 1 | 2023 | 2 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2023 | 20 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2023 | 10 | 0.060 |
Why?
|
| Platelet Factor 4 | 1 | 2023 | 1 | 0.060 |
Why?
|
| Osteopontin | 1 | 2023 | 1 | 0.060 |
Why?
|
| Interferon Regulatory Factors | 1 | 2023 | 19 | 0.060 |
Why?
|
| Intestines | 1 | 2023 | 18 | 0.060 |
Why?
|
| Antibodies | 1 | 2022 | 11 | 0.060 |
Why?
|
| Oligonucleotides | 1 | 2022 | 7 | 0.060 |
Why?
|
| TRPP Cation Channels | 1 | 2022 | 3 | 0.060 |
Why?
|
| CD24 Antigen | 1 | 2022 | 5 | 0.060 |
Why?
|
| Pericytes | 1 | 2022 | 1 | 0.050 |
Why?
|
| Myocardium | 1 | 2022 | 28 | 0.050 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2022 | 5 | 0.050 |
Why?
|
| Hematopoiesis | 1 | 2022 | 23 | 0.050 |
Why?
|
| Gallbladder | 1 | 2021 | 1 | 0.050 |
Why?
|
| Disease Management | 1 | 2021 | 3 | 0.050 |
Why?
|
| Congenital Abnormalities | 1 | 2021 | 9 | 0.050 |
Why?
|
| Fetal Growth Retardation | 1 | 2021 | 15 | 0.050 |
Why?
|
| Organogenesis | 1 | 2021 | 9 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 15 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 19 | 0.050 |
Why?
|
| Thrombocythemia, Essential | 1 | 2021 | 3 | 0.050 |
Why?
|
| Polycythemia Vera | 1 | 2021 | 4 | 0.050 |
Why?
|
| Multifactorial Inheritance | 1 | 2021 | 42 | 0.050 |
Why?
|
| Homeodomain Proteins | 1 | 2021 | 56 | 0.050 |
Why?
|
| Pancreas, Exocrine | 1 | 2021 | 1 | 0.050 |
Why?
|
| Endothelium | 1 | 2021 | 6 | 0.050 |
Why?
|
| Virus Internalization | 1 | 2021 | 3 | 0.050 |
Why?
|
| Serine Endopeptidases | 1 | 2021 | 4 | 0.050 |
Why?
|
| Virus Replication | 1 | 2021 | 13 | 0.050 |
Why?
|
| Stromal Cells | 1 | 2021 | 13 | 0.050 |
Why?
|
| Cerebellar Neoplasms | 1 | 2021 | 12 | 0.050 |
Why?
|
| Alarmins | 1 | 2020 | 3 | 0.050 |
Why?
|
| Medulloblastoma | 1 | 2021 | 18 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 20 | 0.050 |
Why?
|
| Clathrin | 1 | 2020 | 1 | 0.050 |
Why?
|
| Synaptic Vesicles | 1 | 2020 | 1 | 0.050 |
Why?
|
| Dioxygenases | 1 | 2020 | 1 | 0.050 |
Why?
|
| Inhibitory Postsynaptic Potentials | 1 | 2020 | 1 | 0.050 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2020 | 3 | 0.050 |
Why?
|
| Patch-Clamp Techniques | 1 | 2020 | 5 | 0.050 |
Why?
|
| Coenzyme A-Transferases | 1 | 2020 | 1 | 0.050 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2020 | 2 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2020 | 2 | 0.050 |
Why?
|
| RNA, Antisense | 1 | 2020 | 5 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 1 | 2020 | 21 | 0.050 |
Why?
|
| LIM Domain Proteins | 1 | 2020 | 11 | 0.050 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2020 | 21 | 0.050 |
Why?
|
| Cell Survival | 1 | 2020 | 45 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2020 | 30 | 0.050 |
Why?
|
| Cell Cycle | 1 | 2019 | 31 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2019 | 9 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2020 | 65 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 5 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2019 | 6 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2019 | 12 | 0.040 |
Why?
|
| Cholesterol, Dietary | 1 | 2019 | 1 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 29 | 0.040 |
Why?
|
| Dietary Carbohydrates | 1 | 2019 | 7 | 0.040 |
Why?
|
| Dietary Fats | 1 | 2019 | 10 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 8 | 0.040 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2019 | 16 | 0.040 |
Why?
|
| Sepsis | 1 | 2019 | 6 | 0.040 |
Why?
|
| Sirolimus | 1 | 2019 | 6 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 6 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2019 | 11 | 0.040 |
Why?
|
| Interleukin-10 | 1 | 2019 | 12 | 0.040 |
Why?
|
| Purines | 1 | 2019 | 4 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2019 | 22 | 0.040 |
Why?
|
| Glycolysis | 1 | 2019 | 11 | 0.040 |
Why?
|
| Transposases | 1 | 2019 | 7 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2019 | 14 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2019 | 55 | 0.040 |
Why?
|
| Age Factors | 1 | 2019 | 56 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2019 | 62 | 0.040 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2018 | 6 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2018 | 15 | 0.040 |
Why?
|
| Cyclins | 1 | 2018 | 4 | 0.040 |
Why?
|
| Obesity | 1 | 2019 | 86 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 28 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2018 | 120 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2019 | 146 | 0.040 |
Why?
|
| Sulfoxides | 1 | 2018 | 1 | 0.040 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2018 | 4 | 0.040 |
Why?
|
| Growth Plate | 1 | 2017 | 1 | 0.040 |
Why?
|
| Weaning | 1 | 2017 | 2 | 0.040 |
Why?
|
| Disease Progression | 1 | 2018 | 72 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2017 | 15 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2018 | 191 | 0.040 |
Why?
|
| Colony-Forming Units Assay | 1 | 2017 | 3 | 0.040 |
Why?
|
| Phlorhizin | 1 | 2017 | 1 | 0.040 |
Why?
|
| Insulin Resistance | 1 | 2018 | 64 | 0.040 |
Why?
|
| Cell Division | 1 | 2017 | 22 | 0.040 |
Why?
|
| Calcium Channels | 1 | 2017 | 9 | 0.040 |
Why?
|
| Valproic Acid | 1 | 2017 | 9 | 0.040 |
Why?
|
| Calcium | 1 | 2017 | 42 | 0.040 |
Why?
|
| Rats | 1 | 2017 | 164 | 0.040 |
Why?
|
| Pancreatic Ducts | 1 | 2016 | 1 | 0.040 |
Why?
|
| Acinar Cells | 1 | 2016 | 2 | 0.040 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2016 | 4 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2016 | 13 | 0.040 |
Why?
|
| AC133 Antigen | 1 | 2016 | 2 | 0.040 |
Why?
|
| Spheroids, Cellular | 1 | 2016 | 3 | 0.040 |
Why?
|
| Cell-Free System | 1 | 2016 | 4 | 0.040 |
Why?
|
| Gene Editing | 1 | 2016 | 16 | 0.040 |
Why?
|
| Amidohydrolases | 1 | 2016 | 1 | 0.040 |
Why?
|
| Integrin alpha2 | 1 | 2016 | 1 | 0.040 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2016 | 1 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2016 | 48 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 122 | 0.040 |
Why?
|
| Clone Cells | 1 | 2016 | 20 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 38 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 2015 | 4 | 0.030 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2015 | 11 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 38 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2016 | 40 | 0.030 |
Why?
|
| Doxycycline | 1 | 2015 | 1 | 0.030 |
Why?
|
| Chorioallantoic Membrane | 1 | 2015 | 1 | 0.030 |
Why?
|
| Gene Knock-In Techniques | 1 | 2015 | 4 | 0.030 |
Why?
|
| Chickens | 1 | 2015 | 6 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2015 | 10 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 17 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2013 | 15 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 53 | 0.030 |
Why?
|
| Nucleotide Motifs | 1 | 2013 | 11 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2012 | 12 | 0.030 |
Why?
|
| Genome | 1 | 2013 | 77 | 0.030 |
Why?
|
| Toxins, Biological | 1 | 2011 | 3 | 0.020 |
Why?
|
| Kinetics | 1 | 2011 | 43 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 552 | 0.020 |
Why?
|
| Vitamin D Response Element | 1 | 2009 | 1 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2009 | 4 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2009 | 2 | 0.020 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2009 | 3 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2009 | 6 | 0.020 |
Why?
|
| Feedback, Physiological | 1 | 2009 | 7 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2009 | 11 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 21 | 0.020 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2009 | 13 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2009 | 14 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2009 | 50 | 0.020 |
Why?
|
| Normal Distribution | 1 | 2008 | 2 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2008 | 7 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2008 | 44 | 0.020 |
Why?
|
